New Drug/Misbranded
Similar Posts
Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)
As part of the Accelerating Rare disease Cures (ARC) Program, CDER’s Rare Diseases Team inaugurated the Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D) initiative. Learn more.Dreyer’s Grand Ice Cream, Inc. Issues Allergy Alert on Undeclared Wheat in Haagen-Dazs Chocolate Dark Chocolate Mini Bars in 6 Count Pack
November 3, 2025, Dreyer’s Grand Ice Cream, Inc. is voluntarily recalling a limited number of its Häagen-Dazs Chocolate Dark Chocolate Mini Bars that may contain undeclared wheat. Those with an allergy or severe sensitivity to wheat run the risk of serious or life-threatening allergic reaction if thOSRX Inc. Missoula, MT. 483 issued 11/14/2025
ask Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 11/14/2025
Short Title (70 char) OSRX Inc. Missoula, MT. 483 issued 11/14/2025
FEI Number 3014549846
Firm Name OSRX Inc
Record Type 483
State MT
Establishment Type Outsourcing FacilityRecall Alert: Max Mobility/Permobil Removes All SpeedControl Dials Used with SmartDrive MX2+ Power Assist Devices
SpeedControl Dials used with SmartDrive MX2+ Power Assist Devices may be unresponsive to users and fail to stop or start unexpectedly, causing injuryPatient-Focused Drug Development: Workshop #2 to Discuss Methodologic and Other Challenges Related to Patient Experience Data – 09/18/2025
On September 18 and 19, 2025, the U.S. Food and Drug Administration (FDA) is hosting a virtual public workshop to discuss methodological challenges related to patient experience data encountered, including the submission and evaluation of patient experience data in the context of the benefit-risk assessment and product labeling, as well as other ar